Oleo Bone

Pyridoxine Hydrocloride/Tirzepatide

(25MG/18MG)/ML

Tirzepatide, initially approved by the FDA for type 2 diabetes management, has also gained approval for aesthetic purposes, particularly in weight loss. This highly effective medication targets key hormones involved in regulating appetite, leading to significant reductions in body weight. A pivotal study highlighted its efficacy: participants undergoing intensive lifestyle changes followed by weekly Tirzepatide injections lost an average of 27% of their total body weight, about 64 pounds, over 72 weeks. This study, “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial,” published in JAMA in 2024, demonstrates Tirzepatide’s potential as an effective weight loss treatment. The combination of pharmacological intervention with lifestyle modifications proved crucial in achieving these results. Tirzepatide’s approval for aesthetic use underlines its role in addressing obesity, a condition with significant health and aesthetic implications.

Semaglutide is given through a subcutaneous injection once per week.

Reference:

Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945​​.

 

Single Dose

$225
1-Month Package

12% off

$800
2-Month Package

33% off

$1200
3-Month Package

45% off

$1500